{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:39:04Z","timestamp":1792834744236,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Thymidine kinase 1 (TK1) is a cell-cycle-regulated enzyme involved in DNA synthesis and is closely linked to tumor cell proliferation. This study investigated whether serum TK1 concentration is associated with clinicopathological high-risk features in breast cancer (BC) and whether TK1 changes after neoadjuvant chemotherapy (NACT). This retrospective single center cohort included 410 patients with invasive BC. Serum TK1 was analyzed according to age, lymph node metastasis (LNM), histological grade, Ki-67, circulating tumor cell (CTC) status, tumor size, and BC subtype. Subtypes were analyzed as Luminal A, Luminal B, and a human epidermal growth factor receptor 2 (HER2)-positive\/triple-negative breast cancer (TNBC) high-risk group (25 HER2-positive and 35 TNBC cases). Multivariable linear regression included age, LNM, histological grade, Ki-67, CTC status, and subtype. Normality, sensitivity, and nonparametric analyses were performed. In the full-cohort, serum TK1 was higher in patients aged &lt;35 years, in patients with LNM, in grade II\/III tumors, and in tumors with Ki-67\u2005&gt;\u200530%. The univariable difference among the 3 subtype groups was not statistically significant (ANOVA\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.239); however, after adjustment, the HER2-positive\/TNBC group had higher serum TK1 than Luminal A tumors (\n                      <jats:italic toggle=\"yes\">B<\/jats:italic>\n                      \u2005=\u20050.197, 95% CI 0.103\u20130.291,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). CTC status was not independently associated with TK1 (\n                      <jats:italic toggle=\"yes\">B<\/jats:italic>\n                      \u2005=\u20050.020, 95% CI \u22120.081\u20130.122,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.693). The full-cohort sensitivity model excluding CTC yielded consistent results. In the NACT subgroup, serum TK1 decreased after treatment overall and in both complete response and partial response subgroups. Serum TK1 was independently associated with younger age, LNM, higher histological grade, Ki-67, and the HER2-positive\/TNBC high-risk phenotype. Serum TK1 also decreased after NACT. Because survival, recurrence-free survival, and disease-free survival were not evaluated, these findings support TK1 as a proliferation-related biomarker for risk stratification and treatment response monitoring, but not as definitive evidence of long-term outcome prediction.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050437","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:01:25Z","timestamp":1787968885000},"page":"e50437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Association between thymidine kinase 1 and clinicopathological high-risk features in breast cancer"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1266-2588","authenticated-orcid":false,"given":"Yanze","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5595-5988","authenticated-orcid":false,"given":"Jiaqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Zibo Central Hospital, Zibo, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern.","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jbi\/wbaa110","article-title":"Molecular subtypes of breast cancer: a review for breast radiologists.","volume":"3","author":"Johnson","year":"2021","journal-title":"J. Breast Imaging"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12935-024-03515-x","article-title":"Pan-cancer analysis reveals that TK1 promotes tumor progression by mediating cell proliferation and Th2 cell polarization.","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-023-07200-x","article-title":"The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.","volume":"204","author":"Zhu","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"e0293128","DOI":"10.1371\/journal.pone.0293128","article-title":"TK1 expression influences pathogenicity by cell cycle progression, cellular migration, and cellular survival in HCC 1806 breast cancer cells.","volume":"18","author":"Bitter","year":"2023","journal-title":"PLoS One"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3389\/fonc.2019.01475","article-title":"Knockdown of thymidine kinase 1 suppresses cell proliferation, invasion, migration, and epithelial-mesenchymal transition in thyroid carcinoma cells.","volume":"9","author":"Liu","year":"2019","journal-title":"Front Oncol"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.3390\/jcm10225416","article-title":"Immunohistochemistry for thymidine kinase-1 (TK1): a potential tool for the prognostic stratification of breast cancer patients.","volume":"10","author":"Fanelli","year":"2021","journal-title":"J Clin Med"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3892\/etm.2011.395","article-title":"Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer.","volume":"3","author":"Huang","year":"2012","journal-title":"Exp Ther Med"},{"key":"R10-20261024","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.esmoop.2021.100076","article-title":"Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.","volume":"6","author":"Matikas","year":"2021","journal-title":"ESMO Open"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13578-020-00493-1","article-title":"Thymidine kinase 1 through the ages: a comprehensive review.","volume":"10","author":"Bitter","year":"2020","journal-title":"Cell Biosci"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women.","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group.","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s43556-022-00071-6","article-title":"Therapeutic progress and challenges for triple-negative breast cancer: targeted therapy and immunotherapy.","volume":"3","author":"Yang","year":"2022","journal-title":"Mol Biomed"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/jcla.21587","article-title":"Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.","volume":"27","author":"Bolayirli","year":"2013","journal-title":"J Clin Lab Anal"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13058-017-0913-7","article-title":"Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4\/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.","volume":"19","author":"Bagegni","year":"2017","journal-title":"Breast Cancer Res"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis.","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R21-20261024","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility.","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050437","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:01:19Z","timestamp":1792832479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":19,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050437","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2025-09-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}